Exclusive: ACR Convergence 2024 | Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Conditions
FocusRheum
Guidance
Drug Updates
- Analgesics
- Biologics/DMARDs
Practice Support
- Billing/Coding
- EMRs
- Facility
- Insurance
- QA/QI
- Technology
- Workforce
Opinion
Career
ACR
Search

Phase 2 Results for Mavrilimumab Are In

Mary Beth Nierengarten | Issue: November 2018 | November 19, 2018

Page: 1 2 3 | Single Page

Share:

Filed under:Conditions Drug Updates Rheumatoid Arthritis Tagged with:Biomarkers mavrilimumab

Related Articles

Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data

September 1, 2014

Plus, rheumatology drug news, safety updates

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

January 25, 2021

In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.

A Vessel for Knowledge: The Latest Research & Management Updates for Vasculitis

August 11, 2022

Brendan Antiochos, MD, provided a timely update on research and treatments related to vasculitis, addressing treatments for ANCA-associated vasculitis and giant cell arteritis, COVID-19 vaccination and more.

Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

April 6, 2012

Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.

About Us
Meet the Editors
Issue Archives
Contribute
Advertise
Contact Us

Copyright © 2000-2024 American College of Rheumatology. All rights reserved. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
DEI Statement
Privacy Policy
Terms of Use
Cookie Preferences